FDA approves Tezspire for chronic rhinosinusitis with nasal polyps
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
Subscribe To Our Newsletter & Stay Updated